Lynthera is a biomedical company specializing in the research and development of drug delivery and formulation technology. We have created a novel technology platform for the controlled release of ocular therapeutics. This technology has been demonstrated through our development of a drug delivery contact lens (DDCL) product for the treatment of glaucoma, dry eye, and myopia control. With research support from NIH and NSF leading to positive pre-clinical results, the DDCL is planned for study in a clinical trial of glaucoma patients, followed by future clinical development of dry eye and other indications.

 

Lynthera's technology presents significant opportunities to address needs in the global ocular health and vision market, across prescription eye drugs, OTC drops, and vision care. These fields comprise over $50 billion in annual spending worldwide. In glaucoma ($6 billion market) and dry eye ($4 billion market), the introduction of a DDCL offers advantages to topical eye drops, which are limited by burst release kinetics and a higher frequency of dosing that affects compliance rates. In the OTC drop and contact lens markets, Lynthera’s technology can also be employed to promote controlled release and retention of comfort-enhancing ingredients. Importantly, the application of this technology to lenses, eye drops, and other materials can uniquely address formulation challenges of active ingredients that are otherwise difficult to control, stabilize, or precisely dose – creating benefits for ocular therapeutics and beyond.